About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Study Evaluating Mitoxantrone in Multiple Sclerosis

Study Evaluating Mitoxantrone in Multiple Sclerosis

NCT00146159·7 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Wyeth is now a wholly owned subsidiary of Pfizer

Age

18–55

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Secondary progressive MS in an active stage
EDSS between 3 and 6

You may not be if

Benign or primary progressive MS
Patients with cardiac risk factors
Patients who have already received mitoxantrone

The record

StatusTerminated

PhasePhase 3

Taking part336

StartedMar 2005

UpdatedDec 28, 2007

Conditions

Secondary Progressive Multiple Sclerosis

Where7

Berg, Germany
Berlin, Germany
Düsseldorf, Germany